Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Safe Step Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019. -Issues related to drug shortages, and pharmaceutical procurement processes.
Elijah E. Cummings Lower Drug Costs Now Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
-Pharmacy issues related to H.R 6395/S. 4049, the National Defense Authorization Act for Fiscal Year 2021.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
Source: Senate LDA
-H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019. -Issues related to drug shortages, and pharmaceutical procurement processes.
William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Pharmacy issues related to H.R 6395/S. 4049, the National Defense Authorization Act for Fiscal Year 2021.
William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Pharmacy issues related to H.R 6395/S. 4049, the National Defense Authorization Act for Fiscal Year 2021.
Lower Health Care Costs Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019. -Issues related to drug shortages, and pharmaceutical procurement processes.
Lower Health Care Costs Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to drug shortages, and pharmaceutical procurement processes.
National Defense Authorization Act for Fiscal Year 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Pharmacy issues related to H.R 6395/S. 4049, the National Defense Authorization Act for Fiscal Year 2021.
National Defense Authorization Act for Fiscal Year 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Pharmacy issues related to H.R 6395/S. 4049, the National Defense Authorization Act for Fiscal Year 2021.
Phair Pricing Act of 2019
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Medical utilization management and Medicare Advantage program policy and operations. -Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. -Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. -Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2020 (CMS-4185-P). -Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act. -Medicare Part B reforms. S 476, the Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; S.657, the Drug Price Transparency Act.
Prescription Drug Price Transparency Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Medical utilization management and Medicare Advantage program policy and operations. -Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. -Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. -Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2020 (CMS-4185-P). -Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act. -Medicare Part B reforms. S 476, the Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; S.657, the Drug Price Transparency Act.
Protecting Consumer Access to Generic Drugs Act of 2019
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act.
Protecting Consumer Access to Generic Drugs Act of 2019
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019. -H.R. 4946, Ensuring Seniors Access to Local Pharmacies Act of 2019. -H.R. 5281, Drug Price Transparency in Medicaid Act of 2019. -H.R. 5304, PBM Transparency in Prescription Drug Costs Act. -Issues related to drug shortages, and pharmaceutical procurement processes.
Protecting Consumer Access to Generic Drugs Act of 2019
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019.
Protecting Consumer Access to Generic Drugs Act of 2019
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019.
Safe Step Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019. -H.R. 4946, Ensuring Seniors Access to Local Pharmacies Act of 2019. -H.R. 5281, Drug Price Transparency in Medicaid Act of 2019. -H.R. 5304, PBM Transparency in Prescription Drug Costs Act. -Issues related to drug shortages, and pharmaceutical procurement processes.
Safe Step Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019.
Safe Step Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019.
National Defense Authorization Act for Fiscal Year 2020
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Pharmacy issues related to S. 1215 and H.R. 2500, the National Defense Authorization Act for Fiscal Year 2020.
National Defense Authorization Act for Fiscal Year 2020
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Pharmacy issues related to S. 1215 and H.R. 2500, the National Defense Authorization Act for Fiscal Year 2020.
Elijah E. Cummings Lower Drug Costs Now Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019.
Elijah E. Cummings Lower Drug Costs Now Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019. -H.R. 4946, Ensuring Seniors Access to Local Pharmacies Act of 2019. -H.R. 5281, Drug Price Transparency in Medicaid Act of 2019. -H.R. 5304, PBM Transparency in Prescription Drug Costs Act. -Issues related to drug shortages, and pharmaceutical procurement processes.
Ensuring Seniors Access to Local Pharmacies Act of 2019
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019. -H.R. 4946, Ensuring Seniors Access to Local Pharmacies Act of 2019. -H.R. 5281, Drug Price Transparency in Medicaid Act of 2019. -H.R. 5304, PBM Transparency in Prescription Drug Costs Act. -Issues related to drug shortages, and pharmaceutical procurement processes.
Drug Price Transparency in Medicaid Act of 2019
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019. -H.R. 4946, Ensuring Seniors Access to Local Pharmacies Act of 2019. -H.R. 5281, Drug Price Transparency in Medicaid Act of 2019. -H.R. 5304, PBM Transparency in Prescription Drug Costs Act. -Issues related to drug shortages, and pharmaceutical procurement processes.
PBM Transparency in Prescription Drug Costs Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019. -H.R. 4946, Ensuring Seniors Access to Local Pharmacies Act of 2019. -H.R. 5281, Drug Price Transparency in Medicaid Act of 2019. -H.R. 5304, PBM Transparency in Prescription Drug Costs Act. -Issues related to drug shortages, and pharmaceutical procurement processes.
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Medical utilization management and Medicare Advantage program policy and operations. -Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. -Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. -Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2020 (CMS-4185-P). -Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act. -Medicare Part B reforms. S 476, the Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; S.657, the Drug Price Transparency Act.
CREATES Act of 2019
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019. -H.R. 4946, Ensuring Seniors Access to Local Pharmacies Act of 2019. -H.R. 5281, Drug Price Transparency in Medicaid Act of 2019. -H.R. 5304, PBM Transparency in Prescription Drug Costs Act. -Issues related to drug shortages, and pharmaceutical procurement processes.
CREATES Act of 2019
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019.
CREATES Act of 2019
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019.
CREATES Act of 2019
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act.
National Defense Authorization Act for Fiscal Year 2020
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Pharmacy issues related to S. 1215 and H.R. 2500, the National Defense Authorization Act for Fiscal Year 2020.
National Defense Authorization Act for Fiscal Year 2020
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Pharmacy issues related to S. 1215 and H.R. 2500, the National Defense Authorization Act for Fiscal Year 2020.
Prescription Drug Rebate Reform Act of 2019
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019.
Prescription Drug Rebate Reform Act of 2019
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019. -H.R. 4946, Ensuring Seniors Access to Local Pharmacies Act of 2019. -H.R. 5281, Drug Price Transparency in Medicaid Act of 2019. -H.R. 5304, PBM Transparency in Prescription Drug Costs Act. -Issues related to drug shortages, and pharmaceutical procurement processes.
Prescription Drug Rebate Reform Act of 2019
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019.
Lower Health Care Costs Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019.
Lower Health Care Costs Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019.
Lower Health Care Costs Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019. -H.R. 4946, Ensuring Seniors Access to Local Pharmacies Act of 2019. -H.R. 5281, Drug Price Transparency in Medicaid Act of 2019. -H.R. 5304, PBM Transparency in Prescription Drug Costs Act. -Issues related to drug shortages, and pharmaceutical procurement processes.
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019. -H.R. 4946, Ensuring Seniors Access to Local Pharmacies Act of 2019. -H.R. 5281, Drug Price Transparency in Medicaid Act of 2019. -H.R. 5304, PBM Transparency in Prescription Drug Costs Act. -Issues related to drug shortages, and pharmaceutical procurement processes.
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019.
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019.
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act.
Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Medical utilization management and Medicare Advantage program policy and operations. -Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. -Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. -Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2020 (CMS-4185-P). -Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act. -Medicare Part B reforms. S 476, the Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; S.657, the Drug Price Transparency Act.
Preserve Access to Affordable Generics and Biosimilars Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019.
Preserve Access to Affordable Generics and Biosimilars Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019.
Preserve Access to Affordable Generics and Biosimilars Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act.
Preserve Access to Affordable Generics and Biosimilars Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019. -H.R. 4946, Ensuring Seniors Access to Local Pharmacies Act of 2019. -H.R. 5281, Drug Price Transparency in Medicaid Act of 2019. -H.R. 5304, PBM Transparency in Prescription Drug Costs Act. -Issues related to drug shortages, and pharmaceutical procurement processes.
Phair Pricing Act of 2019
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Medical utilization management and Medicare Advantage program policy and operations. -Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. -Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. -Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2020 (CMS-4185-P). -Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act. -Medicare Part B reforms. S 476, the Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; S.657, the Drug Price Transparency Act.
A bill to amend title XXVII of the Public Health Service Act to establish requirements with respect to prescription drug benefits.
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
-Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Medical utilization management and Medicare Advantage program policy and operations. -Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. -Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. -Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2020 (CMS-4185-P). -Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act. -Medicare Part B reforms. S 476, the Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; S.657, the Drug Price Transparency Act.
2020 · second_quarter · Q2
-Pharmacy issues related to H.R 6395/S. 4049, the National Defense Authorization Act for Fiscal Year 2021.
-Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to drug shortages, and pharmaceutical procurement processes.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of, White House Office
Pharmacy issues related to the National Defense Authorization Act for Fiscal Year 2021.
-H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019. -Issues related to drug shortages, and pharmaceutical procurement processes.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
Pharmacy issues related to S. 1215 and H.R. 2500, the National Defense Authorization Act for Fiscal Year 2020.
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019. -H.R. 4946, Ensuring Seniors Access to Local Pharmacies Act of 2019. -H.R. 5281, Drug Price Transparency in Medicaid Act of 2019. -H.R. 5304, PBM Transparency in Prescription Drug Costs Act. -Issues related to drug shortages, and pharmaceutical procurement processes.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Vice President of the U.S.
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019.
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act.
Pharmacy issues related to S. 1215 and H.R. 2500, the National Defense Authorization Act for Fiscal Year 2020.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
-Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Medical utilization management and Medicare Advantage program policy and operations. -Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. -Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. -Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2020 (CMS-4185-P). -Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act. -Medicare Part B reforms. S 476, the Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; S.657, the Drug Price Transparency Act.
Pharmacy issues related to the 2019 National Defense Authorization Act and implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Executive Office of the President (EOP), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR), White House Office